Effect of potassium-channel openers on the release of endothelium-derived hyperpolarizing factor in porcine coronary arteries stored in cold hyperkalemic solution.
Hyperkalemic solution is widely used to protect the myocardium during open-heart surgery or to preserve donor hearts during heart or heart/lung transplants. The inhibitory effects of hvperkalemic solution on the release of endothelium-derived hyperpolarizing factor (EDHF) of coronary arteries following deep hypothermic storage (4 degrees C) has been well studied. However, it has not been established whether potassium channel openers have protective effects on the coronary endothelial function after cold storage. This study was designed to examine this. Porcine coronary artery rings were studied in organ baths. Relaxation in response to the EDHF stimulus A23187 (nonreceptor-mediated stimulus calcium ionophore) in thromboxane A2 mimetic U46619 (30 nmol/L)-induced precontraction after incubation with hyperkalemic solution (20 mmol/L) with nicorandil (10 micromol/L) (either at 37 degrees C in the oxygenated organ chamber or at 4 degrees C in a refrigerator for 6 h) was compared with the control. There was significant difference between hyperkalemia group and hyperkalemia with nicorandil group under normothermia (p = .04). The difference was significant in the same solution between normothermia and hypothermia. After incubation in hyperkalemic solution without or with nicorandil, the A23187-induced relaxation was 32.8% +/- 9.1% and 72.6% +/- 16.9%, respectively (N = 8, p < .01). Potassium channel opener can attenuate the inhibitory effect of hyperkalemic solution on the release of EDHF after cold storage.
Long
Cun
C
Anesthesiology and Cardiopulmonary Bypass Laboratory, Cardiovascular Institute and Fuwai Hospital, CAMS and PUMC, Beijing, People's Republic of China. fuwaipb@mx.cei.gov.cn
Li
Wentao
W
Lin
Dao-Ming
DM
Yang
Jiu-Guang
JG
D000818:Animals; D001685:Biological Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000001:Calcimycin / Q000494:pharmacology; D002314:Cardioplegic Solutions / Q000737:chemistry* / Q000494:pharmacology; D003080:Cold Temperature; D003331:Coronary Vessels / Q000187:drug effects* / Q000502:physiology; D006947:Hyperkalemia; D066298:In Vitro Techniques; D009126:Muscle Relaxation / Q000187:drug effects; D020108:Nicorandil / Q000494:pharmacology; D015221:Potassium Channels / Q000187:drug effects*; D013552:Swine; D014665:Vasodilator Agents / Q000494:pharmacology
D001685:Biological Factors; D002314:Cardioplegic Solutions; D015221:Potassium Channels; D014665:Vasodilator Agents; C067410:endothelium-dependent hyperpolarization factor; D020108:Nicorandil; D000001:Calcimycin